INTRODUCTION
Interleukin-16 (also known as lymphocyte chemoattractant factor (LCF)) was first described in 1982 as a T-cell chemoattractant factor produced by antigen and mitogen stimulated lymphocytes [1] . An array of immune and nonimmune cells are now known to express IL-16 as one aspect of an inflammatory response, including CD4 + and CD8 + T cells, eosinophils, monocytes, mast cells and dendritic cells [2] ; [3] ; [4] ; [5] . In addition, IL-16 has been reported to promote the entry of resting CD4+ T cells into the cell cycle, and the up-regulation of IL-2 receptor and major histocompatibility (MHC) class II proteins on cell surfaces [6] ; [7] .
Human IL-16 (hIL-16) is expressed as a 631 amino acid precursor protein and contains three PDZ domains, along with an N-terminal CcN motif, encompassing both CK2 and cdc2 kinase phosphorylation sites, a nuclear localisation signal and an SH3 binding motif ( Figure 1A ) [8] ; [9] . Following cytosolic proteolysis of hIL-16 by caspase-3, a 121 amino acid fragment encompassing the C-terminal PDZ-domain (residues 527-619) is secreted as the mature form of IL-16 [10] . Secreted IL-16 has been reported to bind to CD4 with relatively high affinity [6] ; [11] ; [12] , which is consistent with IL-16 functioning as a pro-inflammatory cytokine. The protein is reported to have two major effects on CD4+ cells: chemoattraction, preferentially of T H 1 cells, and inhibition of CD3/T-cell mediated activation, preferentially of T H 2 cells [13] . Co-incubation of CD4+ cells with an anti-CD4 antibody (OKT4) is reported to lead to a reduction in the magnitude of IL-16-induced cell migration by monocytes [11] . The protein CD4 contains four immunoglobulin (Ig)-like domains (D1-D4), and CD4 derived peptide inhibition studies of IL-16-mediated chemotaxis suggested that IL-16 binds to CD4 D4 [6] . There is also evidence to suggest that chemokine receptor 5 (CCR5), which is expressed on the surface of T H 1 cells, enhances the binding of IL-16 to the co-receptor [14] .
Interestingly, the chemotactic activity of hIL-16 is not associated with a characteristic chemokine structural motif [15] ; [16] . The solution structure of mature hIL-16 has been reported and showed the chemokine to contain a classical PDZ-domain, consisting of a central up-and-down β-sandwich, adjacent to an α-helix [17] .
PDZ-domains typically assist in the assembly of multi-protein signalling complexes, by binding peptides in a groove between the α1-helix and β2-strand, in a process known as β-strand addition [18] . This peptide recognition is mediated by a conserved GLGF-motif termed the 'carboxylate-binding loop', which coordinates a number of hydrogen bonds to the C-terminal carboxylate of the binding peptide. Surprisingly, the typical PDZ-peptide binding groove is blocked by an aromatic side chain in the reported hIL-16 structure, despite conservation of the GLGF-motif.
There is high sequence homology for IL-16 across mammalian species, with over 85% sequence similarity between human and murine IL-16. The extent of the conservation is even higher at the Cterminal peptide-binding interface associated with typical PDZ activity ( Figure 1B ), strongly suggesting a conserved functional importance. However, the reported tight interaction between IL-16 and CD4 (Kd = 230 pM) has been proposed to involve a cluster of residues close to the Cterminus of IL-16 (R 616 RKS 619 ) [19] ; [14] ( Figure  1B ). IL-16 is associated with disease pathogenesis in a number of autoimmune conditions, with expression levels raised in serum from patients with rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus [15] ; [20] ; [21] . The incubation of dendritic cells with a mouse anti-IL-16 monoclonal antibody (mAb 14.1) was reported to result in a significant reduction in cell migration in cultures of epidermal cells [22] . Furthermore, neutralisation of hIL-16 by mAb 14.1 produced a reduction in the T H 1-type inflammatory response [2] and the mAb 14.1 antibody has shown in vivo efficacy in a rodent model of acute kidney injury [23] . The potential of hIL-16 as a therapeutic target in a range of autoimmune conditions has led to the development of a panel of inhibitory monoclonal antibodies. In this communication we report the structure of a promising Fab candidate (c14.1) based on mAb14.1 bound to hIL-16, which reveals an unexpected binding site for the inhibitory antibody on the opposite face of the protein to the proposed CD4 binding site. In addition, the structure of the c14.1Fab-IL-16 complex reveals a significant conformational change in hIL-16, allowing residues from the CDR loops to make extensive contacts in the generic PDZ-domain peptidebinding groove. This raises the possibility of the IL-16 PDZ-domain modifying its activity via a cryptic peptide binding site.
The structural changes induced in hIL-16 by the inhibitory antibody binding also reveal new opportunities for the design of small molecule inhibitors to target hIL-16 activity.
EXPERIMENTAL PROCEDURES

Expression and Purification of human IL-16 (hIL-16)
A recombinant protein corresponding to mature secreted human IL-16 (residues 502-631) with an N-terminal hexahistidine tag was expressed as a soluble product using a pLEICS-01 vector (Protex, University of Leicester) transformed into the E.coli strain BL-21 (DE3) (Novagen). Uniformly 13 15 N) and 6 or 25 ms in F 1 ( 13 C) as appropriate, with the spectra collected over approximately 13 -60h. All datasets were non-uniform sampled to 25% and reconstructed using hmsIST software [26] . Backbone amide chemical shifts for free hIL-16 were consistent with those reported previously. However, all backbone assignments were confirmed using 3D HNCO, CBCACONH and CBCANH experiments, allowing for the full assignment of peaks from the 15 N-1 H TROSY spectra. All NMR data were processed and analysed using NMRPipe [27] and SPARKY (University of California, San Francisco) software.
The minimal shift approach [28] 
Protein Crystallography
Initial crystallisation trials for the c14.1Fab-IL16tr complex were performed at 20 mg/mL using sitting drop vapor diffusion and 96-well block screens (Molecular Dimensions) at 20 o C. Optimal crystals of c14.1Fab-hIL-16tr grew in 16% PEG3350, 0.1 M Bis-Tris-Propane, pH 6.5 and 0.2 M sodium sulphate. A cryoprotectant consisting of 22% v/v ethylene glycol in mother liquor was used. X-ray diffraction data were collected at the Diamond Light Source (Oxford, UK) using beamline I03.
Diffraction data were indexed and integrated in xds [29] and scaled using SCALA [30] . A Matthews Coefficient [31] calculated one molecule of c14.1Fab and one molecule of hIL16tr present in the asymmetric unit. A homology model of c14.1Fab was generated using SWISSMODEL [32] with the deposited antibody structures 4F33 [33] and 1I7Z [34] , used to model the heavy and light chains, respectively. The structure of the c14.1Fab-hIL-16tr complex was determined by molecular replacement, using the program PHASER [35] , with the hIL-16 NMR structure (PDB:1I16) and the c14.1Fab homology model used in the search. Model building and structural refinement was carried out with Coot [36] , PHENIX [37] and REFMAC 5.0 [38] using restrained refinement and isotropic B-factors. Xray data collection and refinement statistics are given in Table 1 .
ELISA-type c14.1mAb-IL-16 binding assays
Wells on Streptavidin HBC plates (Thermo Scientific) were coated overnight at 4 °C with 50 uL of 0.048 -25 µg/mL of recombinant hIL-16 or hIL-16 W600A in Dulbecco's PBS (Thermo Scientific). After blocking with 2% BSA in PBS at RT for 1h, 50 µL of 1 µg/mL c14.1 antibody in Dulbecco's PBS with 0.1% BSA was added to the wells and incubated for 1h at RT. Following incubation with HRP-conjugated anti-mouse (Fc specific) antibodies (Sigma A2304) (1:5,000 dilution) at RT for 1 h, the substrate 3,3′,5,5′-Tetramethylbenzidine (TMB) (Sigma T4444) was added and allowed to develop. Bound proteins were quantified after measuring the absorbance at 450-650nm in a microtiter plate reader (Tecan Saffire), and data were analyzed by GraphPad Prism software.
Flow cytometry analysis of OKT4 antibody and hIL-16 binding to cell surface CD4
Flow cytometry analysis of both hIL-16 and OKT4 antibody binding to cell surface CD4 was performed in duplicate, with 1x10 5 cells per well in FACS buffer (PBS+2%FBS). The OKT4 antibody binds to the D3 domain of CD4. CD4+ve cells were incubated with hIL-16 (3.3ng/mL -33 mg/mL) for 2 hours at 4 o C, followed by biotinylated OKT4 (ebioscience 13-0048) at 500ng/mL final concentration and Streptavidin Alexafluor 488 (Invitrogen S11223) at 2µg/mL final concentration for 30 mins at 4 o C, then analysed using a Millipore guava easyCyte.
RESULTS AND DISCUSSION
Mapping the binding site of the c14.1Fab on hIL-16
Residues from hIL-16 significantly perturbed by the interaction with the c14.1Fab were identified by comparison of 15 N/ 1 H TROSY spectra acquired for the free and antibody bound protein (Figure 2 ). Comprehensive backbone and side chain assignments have been previously reported for hIL-16 [17] , and it proved relatively straightforward to obtain nearly complete backbone resonance assignments for free hIL-16 under our experimental conditions. The observed minimal shifts in backbone amide signals of hIL-16 on complex formation are summarized in the histogram shown in Figure 2A and mapped onto the structure of free hIL-16 clearly identify a contiguous antibody interaction surface. c14.1Fab binding to hIL-16 results in very significant shifts (N-H Δδ ≤ 0.15 ppm) for 15 residues (Gly542, Gly544, Ser546, Gly549, Gly550, Ser553, Asp557, Thr561, Arg564, Met591, Arg596, Trp600, Asn601, Ile603, and Ala605), which form the interaction surface highlighted in Figure 2B . These residues are predominantly localised to the β2 and β3 strands, the β2/β3 loop and the neighbouring α1-helix, collectively forming a continuous patch of ~683 Å 2 on the surface of hIL-16, which is consistent with the size expected for an antibody binding site [39] ; [40] . Surprisingly, the antibody interaction surface identified does not include the residues previously reported to be involved in binding to CD4 (Arg616, Arg617 and Lys618), suggesting that the inhibitory activity of c14.1Fab is not due to direct blocking of CD4 binding to hIL-16.
Structure of the c14.1Fab-hIL-16 complex
To further characterise the interaction of the c14.1Fab with hIL-16 and the molecular basis of the inhibition of activity the structure of the c14.1Fab-hIL-16 complex was solved by X-ray crystallography to 2.1 Å. The published solution structure of mature hIL-16 (PDB:1I16) revealed highly flexible regions on either end of the central PDZ3 domain [17] .
In addition, the NMR interaction studies reported here show that these regions are not involved in c14.1Fab binding and that the PDZ3-domain alone contained the entire antibody interaction site.
Consequently, an isolated PDZ3-domain hIL-16 construct was prepared corresponding to residues 523-622 (hIL16tr) and assessed for crystallographic studies. Size exclusion chromatography confirmed that this truncated form of hIL-16 (hIL-16tr) still bound with high affinity to the c14.1Fab molecule and crystals of the antibody-hIL-16tr complex were obtained that diffracted to 2.1 Å.
Analysis of the diffraction data indicated that the crystals contained one molecule of IL-16tr-c14.1Fab complex in the asymmetric unit. Interpretable electron density was obtained for hIL-16tr residues Glu527 to Ser619, c141.1Fab heavy chain (V H ) residues Glu1 to Ser223 and c14.1Fab light chain (V K ) residues Asp1 to Cys218. The c14.1Fab is a chimeric version of the mouse derived 14.1 inhibitory anti-IL-16 monoclonal antibody. The sequences of the three complementarity determining regions (CDR) in the light (L1, L2, L3) and heavy chains (H1, H2, and H3) can be classified as L1 (Arg24-His38), L2 (Tyr53-Ser60), L3 (Gln93-Thr101), H1 (Gly26-Asn35), H2 (Leu50-Asp66), and H3 (Ser99-Tyr110), respectively (Chothia numbering system [41] ). The structure of the protein complex shows hIL-16tr bound to the conventional antigen binding surface on the c14.1Fab (Figure 3) . The overall structure of the antibody-bound hIL-16tr molecule is very similar to the published hIL-16 free structure (Cα rmsd = 2.09 Å), with the exception of residues 569-575 which appear to be disordered in the crystal structure. The most notable difference in the backbone was for Leu554 (~10.2 Å in Cα positions), which is situated in the β2/β3 loop that was shown to be dynamic in solution [17] . In complex with the c14.1Fab the hIL-16 β2/β3 loop interacts with CDR-H1, which is likely to stabilise this loop region of hIL-16 and may induce a change in conformation compared to the free protein.
Features of the antibody-IL-16 interface
The c14.1Fab-IL-16tr interface buries 876 Å 2 of antibody protein surface from bulk solvent, with 603 Å 2 of the buried surface from the V H domain and 273 Å 2 from the V K domain. In the case of IL-16 a comparable surface of 853 Å 2 is buried by complex formation. This is consistent with the contact surface area estimated from the NMR studies discussed earlier and lies within the typical range of 850±130 Å 2 for an antibody-binding site on target proteins [39] ; [40] . With the exception of CDR-L3, at least one residue from all CDR loops is within 5 Å of hIL-16, with 22 amino acids from the CDR loops losing at least 10 Å 2 of solvent accessibility and making direct contacts with hIL-16. The extensive interface features a mixture of polar and hydrophobic contacts, including the involvement of eight aromatic side chains in the CDR loops, from both the V H (Tyr52, Tyr74, Tyr121, Tyr122 and Tyr127) and V K (Tyr59, Tyr61 and Tyr78) domains. Of these, all are forming hydrogen bonds through their side chain hydroxyl groups, with the exception of Tyr59, Tyr61 and Tyr121. Examples of the interactions seen between the antibody and hIL-16 are illustrated in Figure 4 .
There are 25 residues from hIL-16 within 5 Å of c14.1Fab in the complex, which form a continuous contact surface comprising β-strands β2 and β3, the β2/β3 loop and α1 helix ( Figure 3B ). This antibody binding site on hIL-16 contains many of the residues which show substantial changes in the backbone amide chemical shifts on complex formation (Figure 2A and 2B) , including residues Gly542, Gly544, Ser546, Ser553, Arg564, Arg596, Trp600 and Ile603. However, significant shifts in backbone amide signals were also seen for several residues not directly involved in antibody binding such as residues Gly549, Gly550, Met 591, Asn601 and Ala605. This probably reflects the conformational change in hIL-16 induced by antibody binding and discussed below ( Figure 5 ).
The c14.1Fab interaction surface on hIL-16 includes several basic residues, such as Arg564 and Arg596, which gives the binding site on hIL-16 an overall positive charge. The complimentary face of the antibody includes four acidic residues from the CDR loops (Asp100, Asp103 and Asp109 from CDR-H3; and Glu59 from CDR-L2). Of these, Asp100 and Glu59 form salt bridges with Arg596 and Arg564, respectively, as illustrated for Asp100 and Arg596 in Figure 4B , and which contributes to both the specificity and stability of the complex formed. In total there are ten salt bridges and hydrogen bonds between hIL-16 and the c14.1Fab, together with 13 bridging water molecules, which collectively form a complex hydrogen-bonding and ionic interaction lattice between the two proteins.
A major contributor to the specificity and affinity of the recognition of hIL-16 by the c14.1Fab is shape complementarity at the centre of the binding site, driven predominantly by residues in CDR-H3 (Tyr101, Tyr102 and Asp103 (Figure 4) ). These CDR residues occupy the GLGF cleft on hIL-16, which is a structural feature typical of PDZdomains that commonly bind C-terminal peptides [42] . The previously reported solution structure of free hIL-16 indicated that this cleft on the hIL-16 was too small to accommodate peptide binding or other potential ligands and was also occluded by the indole side chain of Trp600. In addition, there was no evidence of significant mobility of this region in the free hIL-16 solution structures, nor have any peptides been identified that bind to IL-16. Interestingly, the structure of the c14.1Fab-hIL-16 complex reveals a significant antibodyinduced conformational change in the GLGF region of hIL-16, which allows this cleft to accommodate residues from CDR-H3. The localised structural changes observed include a 2 Å shift of the β2-strand to widen the binding site, and a 30 o rotation of the α1-helix to lever the Trp600 side chain from the blocked recognition groove ( Figure 5 ).
These antibody-induced conformational changes in bound hIL-16 permit the phenolic side chain of Tyr102 from CDR-H3 to occupy the remodelled hIL-16 GLGF cleft, formed by Phe545, Ser546, Leu547, Arg596, Ala599, Trp600 and Ile603 ( Figure 4B) . Furthermore, the acidic side chain of Asp103 from CDR-H3 is now able to form a hydrogen bond with the amide backbone of Gly544 in a similar interaction to that seen for peptides binding to the GLGF recognition motif of typical PDZ-domains [42] . Although the interactions seen between the c14.1Fab and hIL-16 do not exactly mimic a typical peptide-PDZ domain complex, the similarities suggest that IL-16 may have the function to bind specific peptides or perhaps more likely is that a more substantial interface formed with a protein partner could include a peptide moiety binding within this site as part of a larger contact surface area. Indeed, a conformational change of a PDZ-domain to accommodate an interaction partner has been observed previously in the Crb 17 peptide binding to the Pals1 PDZdomain [43] . In this instance, Phe318 (occupying the same position as Trp600 in hIL-16) sterically blocks the PDZ-binding groove in the ligand free structure, but adopts a different rotomer conformation away from the groove to accommodate the Crb 17 peptide. Furthermore, the phenyl side chain of Phe318 packs against residues Arg1404 and Leu1405 from Crb 17 , forming one side of the pocket into which the peptide binds.
Potential importance of Trp600 in target recognition
To further probe the importance of the Trp600 side chain in regulating the binding of target protein/peptides to the GLGF region of hIL-16 we produced a W600A variant of hIL-16 and determined the effects on c14.1 antibody binding using an ELISA-based assay. The hIL-16 W600A mutation resulted in a substantial change in the affinity of the interaction between the c14.1 antibody and hIL-16. Removing the blocking tryptophan side chain by substituting the residue with alanine might be expected to increase the affinity of the c14.1 antibody to hIL-16. However, the affinity was observed to decrease by approximately 10-fold, from an EC 50 of 115 nM for native hIL-16 ( Supplementary Figure 1. ). This suggests that the energetic penalty arising from the conformational change induced in hIL-16 on antibody binding is more than offset by the network of Van de Waals interactions between the c14.1Fab CDR-H3 loop residues and the hydrophobic pocket formed by hIL-16 residues Phe545, Leu547, Arg596, Ile603 and, most importantly, the indole side chain from Trp600 ( Figure 4B) .
Impact of the c14.1Fab on IL-16 signalling
The location of the CD4 binding site on hIL-16 was previously probed by assessing the inhibition of IL-16-mediated chemotaxis by linear peptides derived from IL-16, which suggested a role for the R 616 RKS 619 motif [19] . This putative CD4 binding site is located on the opposite face of hIL-16 to the c14.1Fab binding site reported here. This raises intriguing questions regarding the mechanistic basis of the inhibitory activity of the 14.1 antibody.
Minimal shift NMR experiments were used to assess the binding of CD4 domains D1-D4 and CD4 D3D4 to 15 N-labelled hIL-16 and to establish if CD4 binding was affected by c14.1Fab binding. Surprisingly, in samples with a 5-molar excess of either CD4 D1-D4 or D3D4 we observed no shifts in the backbone amide signals of hIL-16, indicating no significant interaction between the two proteins under the experimental conditions used (Supplementary Figure 2) . In agreement with the previously published NMR structural studies of hIL-16, the linewidths of the backbone amide NMR signals observed are consistent with a predominantly monomeric hIL-16. Interestingly, some reports suggest that CD4 only binds to multimeric forms of hIL-16 [44] , however the inhibitory c14.1Fab clearly binds to monomeric hIL-16 with high affinity.
Attempts to directly or indirectly observe hIL-16 binding to cell lines expressing CD4 by flow cytometry also detected no interaction between CD4 and hIL-16 (Supplementary Figure 3. ). Fluorescence-activated cell sorting (FACS) experiments showed that recombinant hIL-16 was unable to compete off bound anti-CD4 antibody OKT4, despite concentrations of hIL-16 of up to 100 mg/mL. Previous studies have suggested that IL-16 dimerisation or tetramerisation may be a requirement for CD4 binding and chemoattractant activity, which could account for the lack of CD4 binding observed here, however, it is unclear as to why mammalian expressed IL-16 would be multimeric. The purified mature hIL-16 expressed in E.coli and used for the work reported here shows no tendency to form multimeric species at concentrations over 1mM, which may suggest that the multimeric forms of hIL-16 reported in mammalian cell extracts may involve other protein partners.
However, the inhibitory c14.1Fab clearly binds with high affinity to the E.coli expressed hIL-16 monomer and neither sterically blocks or perturbs the proposed CD4-binding site on hIL-16.
Structure-based design of small molecules to target the IL-16 functional site recognised by c14.1Fab
The innovative use of antibodies and antibody fragments to identify opportunities for small molecule drug development on a range of proteins selected as attractive therapeutic targets has been proposed recently [45] .
This includes the identification of antibodies that modulate target protein activity by binding to regulatory sites, with structures obtained for these antibody-target protein complexes used to inform and guide the development of small molecule inhibitors or activators as potential drugs.
The structural studies of the c14.1Fab-hIL-16 complex reported here represent an excellent example of the potential of antibody-assisted approaches, with the conformational changes induced by antibody binding revealing new opportunities for small molecule modulation of IL-16 activity. This method of probing the surface of target proteins, using antibodies as tools, to find allosteric and functional pockets is an innovative and exciting prospect and has the potential to revolutionise drug discovery for a wide range of protein targets.
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